Your Unread Messages
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
BJU International, 11/02/09
Nakabayashi M et al. – Ketoconazole has moderate activity as secondary hormonal therapy in patients with CRPC previously treated with taxane–based chemotherapy, although the TTP was short. Previous treatment with oestrogenic therapy is associated with a shorter TTP.
Related Articles
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Relevance Score: 72%
Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection
The Journal of Urology, 11/13/09
Relevance Score: 71%
A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09
Relevance Score: 71%
Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men
The Prostate, 11/02/09
Relevance Score: 71%
Prostate specific antigen for early detection of prostate cancer: longitudinal study
British Medical Journal, 10/08/09
Relevance Score: 71%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
Annals of Oncology, 11/24/09
Effect of Chronic Sildenafil Treatment on Penile Endothelial Function: A Randomized, Double-Blind, Placebo Controlled Study
The Journal of Urology, 11/24/09
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
The Journal of Urology, 11/23/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
Annals of Oncology, 11/24/09
Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
Journal of Clinical Oncology, 11/24/09
Clinical Interpretation of the Expanded Prostate Cancer Index Composite-Short Form Sexual Summary Score
The Journal of Urology, 11/24/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
Annals of Oncology, 11/24/09
Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
Journal of Clinical Oncology, 11/24/09
Clinical Interpretation of the Expanded Prostate Cancer Index Composite-Short Form Sexual Summary Score
The Journal of Urology, 11/24/09
Article Search
Sponsor


See All


